Connor, Clark & Lunn Investment Management (CC&L)’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $116M | Buy |
740,532
+235,092
| +47% | +$35.2M | 0.22% | 102 |
|
|
2026
Q1 | $77.2M | Sell |
505,440
-145,704
| -22% | -$22.3M | 0.18% | 120 |
|
|
2025
Q4 | $89.8M | Buy |
651,144
+609,022
| +1,446% | +$79.8M | 0.24% | 89 |
|
|
2025
Q3 | $5.4M | Buy |
42,122
+13,758
| +49% | +$1.68M | 0.02% | 559 |
|
|
2025
Q2 | $3.43M | Sell |
28,364
-64,632
| -69% | -$7.28M | 0.01% | 691 |
|
|
2025
Q1 | $10.4M | Buy |
92,996
+84,563
| +1,003% | +$9M | 0.05% | 317 |
|
|
2024
Q4 | $821K | Sell |
8,433
-182,884
| -96% | -$19.5M | ﹤0.01% | 1003 |
|
|
2024
Q3 | $22M | Buy |
191,317
+113,260
| +145% | +$12.9M | 0.11% | 156 |
|
|
2024
Q2 | $8.31M | Buy |
78,057
+67,095
| +612% | +$6.73M | 0.03% | 308 |
|
|
2024
Q1 | $1.06M | Sell |
10,962
-66,251
| -86% | -$6.79M | ﹤0.01% | 868 |
|
|
2023
Q4 | $7.8M | Sell |
77,213
-227,937
| -75% | -$22M | 0.04% | 322 |
|
|
2023
Q3 | $31.1M | Sell |
305,150
-167,264
| -35% | -$17M | 0.16% | 117 |
|
|
2023
Q2 | $47.7M | Buy |
472,414
+169,256
| +56% | +$16.9M | 0.24% | 82 |
|
|
2023
Q1 | $27.9M | Sell |
303,158
-316,774
| -51% | -$27.7M | 0.15% | 118 |
|
|
2022
Q4 | $56.2M | Buy |
619,932
+556,154
| +872% | +$46.8M | 0.32% | 58 |
|
|
2022
Q3 | $4.85M | Buy |
63,778
+15,339
| +32% | +$1.27M | 0.03% | 327 |
|
|
2022
Q2 | $4.09M | Buy |
+48,439
| New | +$4.25M | 0.02% | 350 |
|
|
2022
Q1 | – | Sell |
-45,565
| Closed | -$3.99M | – | 1157 |
|
|
2021
Q4 | $3.99M | Buy |
+45,565
| New | +$3.78M | 0.02% | 373 |
|
|
2020
Q3 | – | Sell |
-2,693
| Closed | -$235K | – | 1063 |
|
|
2020
Q2 | $235K | Buy |
2,693
+193
| +8% | +$16.7K | ﹤0.01% | 878 |
|
|
2020
Q1 | $206K | Sell |
2,500
-124,575
| -98% | -$11.1M | ﹤0.01% | 866 |
|
|
2019
Q4 | $12M | Sell |
127,075
-26,425
| -17% | -$2.37M | 0.08% | 166 |
|
|
2019
Q3 | $13.3M | Buy |
153,500
+130,650
| +572% | +$11.7M | 0.09% | 149 |
|
|
2019
Q2 | $2.09M | Sell |
22,850
-96,785
| -81% | -$8.19M | 0.01% | 426 |
|
|
2019
Q1 | $10.3M | Sell |
119,635
-394,089
| -77% | -$31.6M | 0.07% | 186 |
|
|
2018
Q4 | $39.5M | Buy |
513,724
+340,703
| +197% | +$26.5M | 0.27% | 70 |
|
|
2018
Q3 | $13.4M | Buy |
+173,021
| New | +$12.8M | 0.08% | 180 |
|
|
2018
Q1 | – | Sell |
-65,732
| Closed | -$4.95M | – | 778 |
|
|
2017
Q4 | $4.95M | Sell |
65,732
-80,883
| -55% | -$6.1M | 0.03% | 291 |
|
|
2017
Q3 | $11.3M | Buy |
+146,615
| New | +$11.1M | 0.07% | 190 |
|
|
2017
Q2 | – | Sell |
-7,700
| Closed | -$512K | – | 904 |
|
|
2017
Q1 | $512K | Buy |
+7,700
| New | +$513K | ﹤0.01% | 625 |
|
|
2013
Q4 | – | Sell |
-12,797
| Closed | -$904K | – | 747 |
|
|
2013
Q3 | $904K | Buy |
+12,797
| New | +$847K | 0.01% | 277 |
|
Other funds holding NVS
Connor, Clark & Lunn Investment Management (CC&L)'s NVS Position: Q2 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) increased its Novartis (NVS) stake by 47% in Q2 2026, buying an estimated $35.2M and bringing the position to 740,532 shares worth $116M. The position accounts for 0.22% of the portfolio, ranked #102.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NVS in Q3 2013 and has held it in 30 quarters since. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) held 740,532 shares of Novartis worth $116M as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) bought 235,092 Novartis shares in Q2 2026, an estimated $35.2M.
- Novartis made up 0.22% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #102 holding.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Novartis in Q3 2013 and has held it in 30 quarters since.
- 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.